Roivant Sciences (NASDAQ:ROIV) Rating Reiterated by HC Wainwright

Roivant Sciences (NASDAQ:ROIV – Get Rating)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $14.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 60.92% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Citigroup lifted their price objective on shares of Roivant Sciences from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, January 5th. The Goldman Sachs Group lifted their price objective on shares of Roivant Sciences from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, January 19th. JPMorgan Chase & Co. lifted their price objective on shares of Roivant Sciences from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, February 13th. Finally, SVB Leerink lifted their target price on Roivant Sciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, December 19th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.50.

Roivant Sciences Price Performance

Shares of ROIV opened at $8.70 on Thursday. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 0.26. The company’s fifty day simple moving average is $8.45 and its 200 day simple moving average is $6.29. Roivant Sciences has a 1-year low of $2.52 and a 1-year high of $10.00. The company has a market cap of $6.60 billion, a price-to-earnings ratio of -4.89 and a beta of 1.26.

Insiders Place Their Bets

In other news, COO Eric Venker sold 24,037 shares of the business’s stock in a transaction that occurred on Thursday, January 5th. The shares were sold at an average price of $8.02, for a total value of $192,776.74. Following the completion of the transaction, the chief operating officer now directly owns 729,429 shares in the company, valued at approximately $5,850,020.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Vivek Ramaswamy sold 4,000,000 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, February 22nd. The shares were sold at an average price of $7.95, for a total transaction of $31,800,000.00. Following the sale, the director now directly owns 54,409,211 shares of the company’s stock, valued at approximately $432,553,227.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eric Venker sold 24,037 shares of the stock in a transaction that occurred on Thursday, January 5th. The shares were sold at an average price of $8.02, for a total transaction of $192,776.74. Following the completion of the transaction, the chief operating officer now directly owns 729,429 shares of the company’s stock, valued at approximately $5,850,020.58. The disclosure for this sale can be found here. Insiders have sold 4,121,433 shares of company stock worth $32,707,169 over the last ninety days. Corporate insiders own 13.00% of the company’s stock.

Institutional Trading of Roivant Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC boosted its holdings in shares of Roivant Sciences by 493.8% during the 4th quarter. Jane Street Group LLC now owns 88,578 shares of the company’s stock valued at $708,000 after acquiring an additional 73,660 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Roivant Sciences in the 4th quarter worth about $2,423,000. Squarepoint Ops LLC increased its holdings in Roivant Sciences by 189.3% in the 4th quarter. Squarepoint Ops LLC now owns 71,286 shares of the company’s stock worth $570,000 after purchasing an additional 46,646 shares in the last quarter. Legal & General Group Plc increased its holdings in Roivant Sciences by 3.7% in the 4th quarter. Legal & General Group Plc now owns 101,495 shares of the company’s stock worth $811,000 after purchasing an additional 3,578 shares in the last quarter. Finally, Morgan Stanley increased its holdings in Roivant Sciences by 736.9% in the 4th quarter. Morgan Stanley now owns 344,504 shares of the company’s stock worth $2,753,000 after purchasing an additional 303,340 shares in the last quarter. Institutional investors own 52.66% of the company’s stock.

About Roivant Sciences

(Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.